MPL and Thrombocytopenia: In a three-patient series, acute refractory thrombocytopenia occurred shortly after niraparib exposure during paclitaxel/carboplatin; the authors considered an immune-mediated mechanism and noted benefit from early full-dose thrombopoietin-receptor agonists when standard measures failed [11].